Melling Nathaniel, Harutyunyan Levon, Hube-Magg Claudia, Kluth Martina, Simon Ronald, Lebok Patrick, Minner Sarah, Tsourlakis Maria Christina, Koop Christina, Graefen Markus, Adam Meike, Haese Alexander, Wittmer Corinna, Steurer Stefan, Izbicki Jakob, Sauter Guido, Wilczak Waldemar, Schlomm Thorsten, Krech Till
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany; General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Germany.
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
PLoS One. 2015 Jul 31;10(7):e0134614. doi: 10.1371/journal.pone.0134614. eCollection 2015.
Hook microtubule-tethering protein 3 (HOOK3) is an adaptor protein for microtubule-dependent intracellular vesicle and protein trafficking. In order to assess the role of HOOK3 in prostate cancer we analyzed HOOK3 expression by immunohistochemistry on a TMA containing more than 12,400 prostate cancers. Results were compared to tumor phenotype and PSA recurrence as well as aberrations possibly defining relevant molecular subtypes such as ERG status and deletions of 3p13, 5q21, 6q15 and PTEN. HOOK3 immunostaining was negative in normal luminal cells of prostate epithelium, whereas 53.3% of 10,572 interpretable cancers showed HOOK3 expression, which was considered low in 36.4% and high in 16.9% of cases. High-level HOOK3 expression was linked to advanced tumor stage, high Gleason score, high proliferation index, positive lymph node stage, and PSA recurrence (p<0.0001 each). The prognostic role of HOOK3 expression was independent of established clinico-pathological parameters both in preoperative and postoperative settings. Comparisons with molecular features were performed to draw conclusions on the potential function of HOOK3 in the prostate. A strong association with all examined deletions is consistent with a role of HOOK3 for maintaining genomic integrity by contributing to proper centrosome assembly. Finding HOOK3 expression in 74% of ERG positive but in only 38% of ERG negative cancers (p<0.0001) further suggests functional interactions between these genes. In conclusion, the results of our study identify HOOK3 as a strong candidate prognostic marker with a possible role in maintaining genomic integrity in prostate cancer, which may have potential for inclusion into clinical routine assays.
钩状微管拴系蛋白3(HOOK3)是一种衔接蛋白,参与微管依赖性细胞内囊泡运输和蛋白质转运。为了评估HOOK3在前列腺癌中的作用,我们通过免疫组织化学方法,在一个包含超过12400例前列腺癌病例的组织芯片(TMA)上分析了HOOK3的表达情况。将结果与肿瘤表型、前列腺特异性抗原(PSA)复发情况以及可能定义相关分子亚型的畸变情况进行比较,这些分子亚型包括ERG状态以及3p13、5q21、6q15和PTEN的缺失。HOOK3免疫染色在前列腺上皮的正常管腔细胞中呈阴性,而在10572例可解释的癌症病例中,53.3%显示有HOOK3表达,其中36.4%的病例表达水平较低,16.9%的病例表达水平较高。高水平的HOOK3表达与肿瘤晚期、高 Gleason评分、高增殖指数、阳性淋巴结分期以及PSA复发相关(每项p<0.0001)。在术前和术后情况下,HOOK3表达的预后作用均独立于既定的临床病理参数。通过与分子特征进行比较,以得出关于HOOK3在前列腺中的潜在功能的结论。与所有检测到的缺失存在强烈关联,这与HOOK3通过促进中心体的正确组装来维持基因组完整性的作用一致。在74%的ERG阳性癌症中发现有HOOK3表达,但在仅38%的ERG阴性癌症中发现有HOOK3表达(p<0.0001),这进一步表明这些基因之间存在功能相互作用。总之,我们的研究结果表明HOOK3是一个强有力的候选预后标志物,可能在维持前列腺癌基因组完整性方面发挥作用,这可能具有纳入临床常规检测的潜力。